MedPath

Development of tissue engineering therapy to treat patients with delayed consolidation after fracture of long bones.

Phase 1
Conditions
Closed or open Gustilo I ans II humerus, tibial or femur diaphyseal or metaphysodiaphyseal fracture.
MedDRA version: 14.1 Level: PT Classification code 10017081 Term: Fracture delayed union System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
Registration Number
EUCTR2011-005441-13-ES
Lead Sponsor
INSERM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

- age 18 to 65 both sexes
- traumatic isolated closed or open Gustilo I and II humerus, tibial or femur diaphyseal or metaphysodiaphyseal fracture status delayed union or non union
- at least 3 months from acute fracture
- able to provide informed consent, and signed informed consent
- patients (by themselves) should have medical health care coverage to be included in a research study
- able to understand and accept the study constraints
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control
- participation in another therapeutic trial previous 3 months
- delayed union or non-union related to iatrogeny
- segmental bone loss requiring therapy
- vascular or neural injury
- impossibility to meet appointments for the follow up
- other fractures causing interference with weight bearing
- infection
viceral injuries of diseases interfering with callus formation
- history of bone harvesting on iliac crest contraindicating bone-marriw aspiration
- corticoid or immunosuppressive therapy more than one week in the 3 mionths prior ti study inclusion
- history of prior concurrent diagnosis of HIV, Hepatitis B or C infection
- insulin dependent diabetes
- obesity
- autoimmune inflammatory disease
- current treatment by bisphonate or stopped in the 3 months prior to stydy inclusion
- subject legally protected, under legal guardianship, deprived of their liberty by judicial or administrative decision, subject of psychiatric care, or admission a health facility.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath